Immune checkpoint inhibitors block key mediators of immune tolerance, producing antitumor responses and autoimmunelike toxic effects.1 Toxic effects indicate immune activation against host tissues, although it remains controversial whether this off-target activity indicates concurrent antitumor immunity.2-4 Herein, we retrospectively studied whether cutaneous toxic effects correlated with outcomes in patients with advanced melanoma treated with immune checkpoint inhibitors.
Quach HT, Dewan AK, Davis EJ, et al. Association of Anti–Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma. JAMA Oncol. Published online April 18, 20195(6):906–908. doi:10.1001/jamaoncol.2019.0046
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: